Liraglutide LIRA

An FDA-approved injectable medication for diabetes (Victoza) and, at a higher dose, for weight loss (Saxenda). Large studies confirm meaningful blood sugar control and weight loss, with nausea as the most common complaint and a warning label about a thyroid tumor risk seen in animal studies.

Also known as Victoza, Saxenda, Liraglutida, Liraglutidum, Liraglutide recombinant, NNC 90-1170, Liraglutide (rDNA origin)

Effects Lose fat

Routes Subcutaneous

Legal status Prescription drug

WADA Not listed

Molecular Structure of C₁₇₂H₂₆₅N₄₃O₅₁

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C172H265N43O51
Molar mass: 3751
CAS: 204656-20-2
PubChem CID: 16134956
IUPAC name: (2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid
InChIKey: YSDQQAXHVYUZIW-QCIJIYAXSA-N

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 1.8 mg/day (diabetes) or 3 mg/day (weight management)

Reported range 0.6-3 mg/day, titrated upward

Route Subcutaneous injection

Frequency Once daily

Duration Chronic/ongoing (as prescribed)

FDA-approved GLP-1 receptor agonist (Victoza for diabetes, Saxenda for weight management).

Where this comes from FDA prescribing information

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.